News Roundup this Week

• FDA Approves Ketamine Nasal Spray for Standalone Use

• Trump reverses Biden’s Policies on Drug Pricing

• FTC Report Finds PBMs Charge Significant Markups for cancer, HIV and other Drugs

• Walgreens Faces DOJ Lawsuit Over Prescription Practices: The U.S. Department of Justice has filed a lawsuit against Walgreens, alleging the company filled millions of unlawful prescriptions in violation of the Controlled Substances Act and sought improper reimbursements from federal health programs, violating the False Claims Act. The lawsuit seeks significant penalties for each invalid prescription. Walgreens has responded, emphasizing its protocols for reporting suspicious prescribers and expressing concerns about the expectations placed on pharmacists.

• NCPA Joins Class Action Suit Against GoodRx and Leading PBMs: The National Community Pharmacists Association (NCPA) has joined a class-action lawsuit against GoodRx and major pharmacy benefit managers (PBMs), including CVS Caremark, Express Scripts, MedImpact Healthcare Systems, and Navitus Health Solutions. The lawsuit alleges that these entities engaged in practices that harm independent pharmacies and manipulate drug pricing.

Featured Compounding Formula

Thank you